Please assess the completion status of the following clinical trial:

Trial Title: Refractory Urge Incontinence and Botox Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women~* Detrusor overactivity incontinence confirmed by urodynamic testing~* Symptoms refractory to standard first- and second-line treatments~* 6 or more urge incontinence episodes on 3-day bladder diary~* Normal neurological examination~Exclusion Criteria:~* Urinary retention~* Allergy to Botox (Botulinum Toxin A)~* Previous bladder treatment with Botox (Botulinum Toxin A) in the past year~* Pregnancy or planning pregnancy within next year~* Neurologic disease with impaired neurotransmission

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botox A (Type: EXPERIMENTAL): up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).